Temperature control is an active treatment to achieve and maintain a specific temperature of a patient for a certain period of time, in order to improve health outcomes.
Using temperature control can lower patient temperature thereby reducing fever levels. Temperature reduction slows down the metabolism and oxygen demand in the brain, reduces oxidative stress and fluid supply to the brain and reduces glutamate, potassium and calcium toxicity after oxygen deficiency and elevated body temperature.
TEQCool’s intended treatment is designed for severely brain-injured patients, suffering from refractory fever, cared for at neuro–intensive care units.
Guidelines for the use of temperature control in these patients vary significantly, but can encompass indications such as severe traumatic brain injury (TBI), intracerebral hemorrhage, subarachnoid hemorrhage, ischemic stroke etc.
Temperature control is also used in other indications such as cardiac arrest, intensive care patients with difficult-to-treat fever and treatment of hypoxic ischemic encephalopathy (HIE) after asphyxia at birth. Significant technical and clinical research is undertaken to evaluate new indications where cooling treatment could be beneficial.